Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 /
抑制剂/激动剂
肿瘤
/
抗感染
DNA损伤 细胞周期 自噬 抗体-药物偶联物 肿瘤表观遗传和基因调控
/
DNA
ADC毒素 自噬 Antibacterial 拓扑异构酶
/ Daunorubicin

柔红霉素 /Daunorubicin {[allProObj[0].p_purity_real_show]}

货号：A208987 同义名： Daunomycin;RP 13057

Daunorubicin, a topoisomerase II inhibitor, inhibits both DNA and RNA synthesis and inhibits DNA synthesis with Ki of 0.02 μM.

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Daunorubicin 化学结构 CAS号：20830-81-3
Daunorubicin 化学结构
CAS号：20830-81-3
Daunorubicin 3D分子结构
CAS号：20830-81-3
Daunorubicin 化学结构 CAS号：20830-81-3
Daunorubicin 3D分子结构 CAS号：20830-81-3
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} 		{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Daunorubicin 纯度/质量文件 产品仅供科研

货号：A208987 标准纯度： {[allProObj[0].p_purity_real_show]}
批次查询： 批次纯度:

全球学术期刊中引用的产品

• Nat. Biomed. Eng., 2024, 8, 1412-1424. Ambeed. [ A538667 , A631746 ]
• JMC, 2024. Ambeed. [ A833302 , A475501 , A341986 , A356070 ]
• BMC Cancer, 2024, 24(1): 1415. Ambeed. [ A809692 , A209020 ]
• J. Am. Soc. Mass Spectrom., 2024, 35(12): 3192-3202. Ambeed. [ A166127 , A902473 , A753371 , A961334 , A292945 , A230770 , A300620 , A1114580 , A1159765 , A206238 ]
• PloS One, 2024, 19(11): e0308060. Ambeed. [ A302917 ]
更多 >
产品名称 DNA synthesis ↓ helicase ↓ RdRp ↓ ribonucleotide reductase ↓ tRNA synthetase ↓ YB-1 ↓ 其他靶点 纯度
Fexinidazole ✔ 98%
Daptomycin ✔ 98%
Blasticidin S·HCl ✔ 98%
Metronidazole ✔ 98%
Daunorubicin HCl +++

DNA synthesis, Ki: 20 nM

 		98%
Triglycidyl isocyanurate ✔ p53 98+%
Nedaplatin ✔ 99%+
Bendamustine ✔ 98+%
Trifluridine ✔ 98%
Robinetin ✔ 99%+
Carboplatin ✔ 99%
Cidofovir ✔ 99%
Cisplatin ✔ 99%
Cytarabine ++++

DNA synthesis, IC50: 16 nM

 		98%
Acelarin ++++

DNA synthesis, EC50: 0.2 nM

 		99%+
Oxaliplatin ✔ 98%
YK-4-279 ✔ 99%+
ML216 +

BLMfull-length, IC50: 2.98 μM

BLM636-1298, IC50: 0.97 μM

 		99%+
RK-33 ✔ 98%
Brr2-IN-3 ✔ 99%+
Phen-DC3 Trifluoromethanesulfonate ✔ 98%
Favipiravir ✔ 97%
Suramin sodium salt ++

RdRp, IC50: 0.26 μM

 		99%+
Clofarabine ++

Ribonucleotide reductase, IC50: 65 nM

 		97%
Didox ✔ 98%
(E)-3-AP ✔ 97%
Halofuginone +++

prolyl-tRNA synthetase, Ki: 18.3nM

 		99%+
BC-LI-0186 +++

Leucyl-tRNA synthetase, Kd: 42.1 nM

Leucyl-tRNA synthetase, IC50: 46.11 nM

 		98%
SU056 +

YB-1, IC50: 1.73 μM

 		98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。
产品名称 Autophagy ↓ 其他靶点 纯度
SBI-0206965 +++

ULK2, IC50: 711 nM

ULK1, IC50: 108 nM

 		97%
Hydroxychloroquine sulfate ✔ 99%
Valproic acid sodium ✔ HDAC 97%
PFK-015 ++

PFKFB3, IC50: 207 nM

 		99%+
MRT68921 hydrochloride ++++

ULK2, IC50: 1.1 nM

ULK1, IC50: 2.9 nM

 		99%+
ROC-325 ✔ 99%+
Autophinib +++

Autophagy, IC50: 40 nM

 		97%
Lys05 ✔ 99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。
产品名称 Topo I ↓ Topo II ↓ Topo IV ↓ Topoisomerase ↓ 其他靶点 纯度
Ellagic acid ✔ 98%
β-Lapachone ✔ 99%+
(s)-10-hydroxycamptothecin ✔ 98+%
Camptothecin ++

Topo I, IC50: 0.68 μM

 		98%
Betulinic acid ++

Eukaryotic topoisomerase I, IC50: 5 μM

 		98%
Topotecan ++++

Topo I (DU-145 Luc cells), IC50: 2 nM

Topo I (MCF-7 Luc cells), IC50: 13 nM

 		98%
Irinotecan HCl Trihydrate ✔ 98%
SN-38 ✔ 98%
Levofloxacin hydrate ✔ 98%
Dexrazoxane ✔ 99%+
Ofloxacin ✔ 98+%
Enoxacin ✔ 99%+
Flumequine +

Topo II, IC50: 15 μM

 		98%
Levofloxacin ✔ 97%
Etoposide ✔ 98%
Pefloxacin mesylate dihydrate ✔ 99+%
Marbofloxacin ✔ 98+%
Voreloxin HCl ✔ 98%
Mitoxantrone dihydrochloride ✔ PKC 98%
Nalidixic acid ✔ 98%
Doxorubicin ✔ 98%
Novobiocin sodium ✔ 95%
Amonafide ✔ 99%+
Pirarubicin ✔ 98%+
Idarubicin HCl +++

Topo II (MCF-7 cells), IC50: 3.3 ng/mL

 		99%+
Genistein ✔ EGFR 98%
Teniposide ✔ 98%
Moxifloxacin ✔ 98%
Ciprofloxacin ✔ 98%
Clinafloxacin ✔ 97%
Gatifloxacin ✔ 98%
Daunorubicin HCl +++

DNA synthesis, Ki: 20 nM

 		98%
Epirubicin HCl ✔ 99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Daunorubicin 生物活性

描述 Daunorubicin, a topoisomerase II inhibitor, inhibits both DNA and RNA synthesis and inhibits DNA synthesis with Ki of 0.02 μM.

Daunorubicin 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT02198482 Acute Myeloid Leukemia (AML) ... 展开 >> High-risk Myelodysplastic Syndrome (MDS) 收起 << Phase 2 Terminated(development program... 展开 >> of study drug volasertib was stopped by Boehringer Ingelheim due to manufacturing problems) 收起 << - Germany ... 展开 >> Hospital Aschaffenburg Aschaffenburg, Germany, 63739 Helios Hospital Bad Saarow Bad Saarow, Germany, 15526 Vivantes Hospital Am Urban Berlin, Germany, 10967 Vivantes Hospital Neukölln Berlin, Germany, 12351 Charite Berlin Campus Virchow Hospital Berlin, Germany, 13353 Knappschaftskrankenhaus Bochum-Langendeer Bochum, Germany, 44892 University Hospital Bonn Bonn, Germany, 53105 Community Hospital Braunschweig Braunschweig, Germany, 38114 Hospital Darmstadt Darmstadt, Germany, 64283 University Hospital Düsseldorf Düsseldorf, Germany, 40225 Hospital Essen, Protestant Hospital Essen-Werden Essen, Germany, 45239 Hospital Esslingen Esslingen, Germany, 73730 Malteser Hospital St. Franziskus Flensburg, Germany, 24939 Hospital Frankfurt-Höchst Frankfurt, Germany, 65929 Medical Care Unit Osthessen Fulda, Germany, 36043 University Hospital Gießen Gießen, Germany, 35392 Wilhelm-Anton-Hospital Goch Goch, Germany, 47574 University Hospital Göttingen Göttingen, Germany, 37075 University Hospital Hamburg-Eppendorf Hamburg, Germany, 20246 Asklepios Hospital Altona Hamburg, Germany, 22763 Hospital Hanau Hanau, Germany, 63450 KRH Hospital Siloah-Oststadt-Heidehaus Hannover, Germany, 30459 Hannover Medical School Hannover, Germany, 30625 SLK-Hospital Heilbronn Heilbronn, Germany, 74078 Marienhospital Herne Herne, Germany, 44625 University Hospital des Saarlandes Homburg/Saar, Germany, 66421 Community Hospital Karlsruhe Karlsruhe, Germany, 76133 University Hospital Schleswig-Holstein Kiel, Germany, 24105 Caritas Hospital Lebach Lebach, Germany, 66822 Hospital Lippe-Lemgo Lemgo, Germany, 32657 University Hospital Magdeburg Magdeburg, Germany, 39120 University Hospital Johannes Gutenberg Mainz Mainz, Germany, 55131 Johannes Wesling Hospital Minden Minden, Germany, 32429 Stauferklinikum Schwäbisch-Gmünd Mutlangen, Germany, 73557 Hospital Schwabing München, Germany, 80804 Hospital rechts der Isar München München, Germany, 81675 Hospital Oldenburg Oldenburg, Germany, 26133 Hospital Passau Passau, Germany, 94032 Hospital Stuttgart Stuttgart, Germany, 70174 Diakonie Hospital Stuttgart Stuttgart, Germany, 70176 Hospital Traunstein Traunstein, Germany, 83278 Mutterhaus der Borromäerinnen Trier, Germany, 54290 Hospital Barmherzige Brüder Trier Trier, Germany, 54292 University Hospital Tübingen Tübingen, Germany, 72076 University Hospital Ulm Ulm, Germany, 89081 收起 <<
NCT02236013 Acute Myeloid Leukemia Phase 1 Recruiting July 2022 United States, California ... 展开 >> Site US10003 Recruiting Los Angeles, California, United States, 90095 United States, Connecticut Site US10013 Recruiting New Haven, Connecticut, United States, 06520 United States, Illinois Site US10004 Recruiting Chicago, Illinois, United States, 60611 United States, Kansas Site US10009 Recruiting Westwood, Kansas, United States, 66205 United States, Maryland Site US10001 Recruiting Baltimore, Maryland, United States, 21231 United States, New York Site US10002 Recruiting New York, New York, United States, 10032 United States, Ohio Site US10014 Recruiting Cleveland, Ohio, United States, 44106 Site US10008 Withdrawn Columbus, Ohio, United States, 43201 United States, Oklahoma Site US10019 Recruiting Oklahoma City, Oklahoma, United States, 73104 United States, Pennsylvania Site US10006 Recruiting Philadelphia, Pennsylvania, United States, 19104 United States, Texas Site US10010 Recruiting San Antonio, Texas, United States, 78229 收起 <<
NCT00037583 Acute Myeloid Leukemia Phase 2 Completed - -

Daunorubicin 参考文献

[1]Lehmann M, Vilar Kde S, et al. Activity of topoisomerase inhibitors daunorubicin, idarubicin, and aclarubicin in the Drosophila Somatic Mutation and Recombination Test. Environ Mol Mutagen. 2004;43(4):250-7.

[2]Gervasoni JE Jr, Hindenburg AA, et al. An effective in vitro antitumor response against human pancreatic carcinoma with paclitaxel and daunorubicin by induction of both necrosis and apoptosis. Anticancer Res. 2004 Sep-Oct;24(5A):2617-26.

Daunorubicin 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.90mL

0.38mL

0.19mL

9.48mL

1.90mL

0.95mL

18.96mL

3.79mL

1.90mL

Daunorubicin 技术信息

CAS号20830-81-3
分子式C27H29NO10
分子量 527.52
别名 Daunomycin;RP 13057;Rubidomycin
运输蓝冰
存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Keep in dark place,Sealed in dry,2-8°C
溶解度
动物实验配方

Tags: Daunorubicin | Daunomycin;RP 13057;Rubidomycin | Topoisomerase | Autophagy | DNA/RNA Synthesis | Antibacterial | AmBeed-信号通路专用抑制剂 | Daunorubicin 纯度/质量文件 | Daunorubicin 亚型比较 | Daunorubicin 生物活性 | Daunorubicin 临床数据 | Daunorubicin 参考文献 | Daunorubicin 实验方案 | Daunorubicin 技术信息

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 Ambeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z